Solos Endoscopy, Inc
BOSTON, MA, United States, via ETELIGIS INC., 11/24/2014 – – Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.
Prominent Doctors from around the Country will be discussing the keys to identifying the cause of breast cancer and determining methods of prevention. Researchers believe that Breast Cancer Prevention lies in understanding the normal human breast and how it develops malignancy. New technologies for DNA/RNA analysis and procedures to sample the human breast are opening up promising new avenues for exploration. The Solos Endoscopy MammoView® Breast Endoscopy System can offer women a positive prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView® Breast Endoscopy System allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
The International Symposium on the Breast calls upon a multidisciplinary and international group of iconoclastic researchers, clinical scientists, and advocates, and challenges participants to formulate new technical approaches to the study of the normal and high-risk breast. Some of the confirmed Speakers at the symposium will include the following:
Mina Bissell, PhD; Lawrence Berkeley National Laboratory
Ellen Carpenter, PhD; University of California Los Angeles
Robert Chatterton, PhD; Northwestern University
Susan Clare, MD, PhD; Northwestern University
William B. Coleman, PhD; University of North Carolina
Sheldon Feldman, MD; Columbia University
Barry Gusterason, PhD; Western Infirmary, Glasgow, Scotland
Sarah Highlander, PhD; Baylor College of Medicine
Ann Hopkins, PhD; Royal College of Surgeons, Ireland
Donald Ingbert, MD, PhD; Harvard University
“I would like to thank the Dr. Susan Love Research Foundation for inviting us to participate in this extremely important Symposium on Breast Health. We believe the early detection that the MamoView® affords its patients gives women the most options when it comes to determining their final treatment,” stated Robert Segersten, President of Solos Endoscopy.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada. The initial Certification came at the conclusion of a lengthy audit with TUV SUD America this past year. The annual audit included a comprehensive review of the Solos Endoscopy’s Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union’s Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282).
Solos Endoscopy has posted its Certificate from TUV America on its website (http://www.solosendoscopy.com)
About Solos Endoscopy, Inc.:
Solos Endoscopy has celebrated its 25th year of providing quality innovative healthcare instruments to hospitals across the country. For more than 25 years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company’s website at: www.solosendoscopy.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company’s Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
Solos Endoscopy, Inc.
SOURCE: Solos Endoscopy, Inc.